Gastrodin’s Regulation of RAS–SIRT3 and Inflammatory Mediators in Reactive Astrocytes

Study Background and Research Question

Neuroinflammation is a hallmark of many central nervous system (CNS) disorders, with reactive astrocytes and microglia playing pivotal roles in orchestrating inflammatory responses. The renin-angiotensin system (RAS), classically associated with cardiovascular homeostasis, is increasingly recognized for its involvement in CNS inflammation and neurodegeneration. Within the RAS, the angiotensin II type 1 receptor (AT1) is a major signaling node mediating proinflammatory and neurotoxic effects. Gastrodin, a bioactive component from Gastrodia elata, is known for its anti-inflammatory and neuroprotective properties, but its influence on astrocyte–microglia signaling through the RAS–SIRT3 axis had not been fully elucidated. The reference study (Zuo et al., 2024) addressed whether gastrodin modulates RAS components, SIRT3, and downstream inflammatory markers in reactive astrocytes, particularly via microglial activation.

Key Innovation from the Reference Study

The central innovation lies in dissecting how gastrodin affects the molecular crosstalk between microglia and astrocytes through the RAS–SIRT3 pathway. The authors demonstrated that gastrodin not only downregulates proinflammatory mediators in astrocytes exposed to activated microglia but also selectively modulates RAS components—specifically suppressing AT1 receptor signaling while enhancing neurotrophic factors. This dual action positions gastrodin as a modulator of both inflammation and neuroprotection in the CNS microenvironment. Notably, the study provides direct evidence that pharmacological inhibition of AT1, using Azilsartan (TAK-536), recapitulates key aspects of gastrodin’s regulatory effect, highlighting the therapeutic and experimental significance of targeting AT1 in neuroinflammation research.

Methods and Experimental Design Insights

The study utilized a well-structured in vitro model combining TNC-1 rat astrocytes and BV-2 mouse microglia. Conditioned medium (CM) from lipopolysaccharide (LPS)-activated BV-2 cells was used to induce reactive astrocyte phenotypes, simulating the inflammatory CNS milieu. Key techniques included:

• Quantitative PCR, western blotting, and immunofluorescence to assess expression of RAS components (angiotensinogen, ACE, AT1, and AT2 receptors), SIRT3, A1/A2 astrocyte markers (C3, S100A10), proinflammatory cytokines, and neurotrophic factors (IGF-1, BDNF).
• Pharmacological intervention with gastrodin and, crucially, Azilsartan as a selective AT1 receptor antagonist, to probe pathway specificity.

This design allowed for dissection of both microglia-to-astrocyte signaling and the effect of selective pathway inhibition, providing a clear framework for mechanistic and translational interpretation.

Core Findings and Why They Matter

Exposure of TNC-1 astrocytes to CM from LPS-activated BV-2 microglia led to:

• Upregulation of angiotensinogen, ACE, AT1 receptor, SIRT3, C3, and proinflammatory cytokines, alongside elevated neurotrophic factors, indicating a robust inflammatory and reactive astrocyte response.
• Downregulation of AT2 receptor and S100A10, markers associated with anti-inflammatory and neuroprotective A2 astrocyte phenotypes.

Gastrodin treatment of BV-2 microglia prior to CM collection mitigated these changes: it reduced expression of proinflammatory mediators, C3, and AT1, while restoring or enhancing SIRT3, IGF-1, and BDNF, and normalizing AT2 and S100A10 levels. This suggests gastrodin shifts the astrocyte phenotype towards a less inflammatory, more neuroprotective state via modulation of the RAS–SIRT3 axis.

Importantly, direct inhibition of AT1 using Azilsartan mirrored the effects of gastrodin on C3 and S100A10 expression, confirming the centrality of AT1 signaling in astrocyte polarization and inflammatory mediator production. These findings consolidate the value of AT1 antagonists in dissecting RAS-driven neuroinflammatory mechanisms and in designing experimental interventions for CNS disease models.

Comparison with Existing Internal Articles

Recent internal resources expand on the experimental and translational utility of Azilsartan (TAK-536) in CNS and cardiovascular research:

• The guide "Azilsartan (TAK-536): Protocols and Troubleshooting in CNS RAS Models" details workflow optimizations for AT1 signaling studies and highlights troubleshooting strategies that align with the current study’s approach to reactive astrocyte–microglia systems.
• "Azilsartan in RAS–SIRT3 Neuroinflammation: Mechanistic and Strategic Insights" provides a broader context for the translational relevance of RAS–SIRT3 modulation in CNS disease, echoing the importance of precise AT1 antagonism as demonstrated in the reference study.
• Protocol optimization for astrocyte–microglia models using Azilsartan is further discussed in "Azilsartan (TAK-536): Protocol Optimization in Astrocyte-Microglia Models", offering practical advice that complements the experimental strategies reported by Zuo et al.

Together, these articles reinforce the practical, reproducible, and mechanistically robust role of Azilsartan in RAS and neuroinflammation research, aligning with the reference paper's findings.

Limitations and Transferability

While the study provides compelling evidence for gastrodin and AT1 antagonism in modulating astrocyte reactivity, several limitations should be considered:

• The use of immortalized cell lines (BV-2 and TNC-1) may not fully recapitulate the complexity of primary CNS tissue or in vivo conditions.
• The study focused on acute inflammatory responses; long-term effects and relevance to chronic neurodegenerative diseases require further validation.
• Species differences between rodent models and human CNS physiology may impact transferability of findings.

Nevertheless, the robust modulation of RAS–SIRT3 and inflammatory markers provides a strong foundation for further mechanistic and preclinical exploration.

Protocol Parameters

• Astrocyte stimulation: Expose TNC-1 astrocytes to conditioned medium from LPS-activated BV-2 microglia for 24 hours to induce reactive phenotypes.
• Gastrodin pretreatment: Pre-treat BV-2 microglia with gastrodin prior to LPS challenge, as per reference protocols, to assess anti-inflammatory modulation.
• AT1 inhibition: Apply Azilsartan (TAK-536) at concentrations validated for AT1 antagonism (e.g., 2–10 μM) in astrocyte cultures to model selective pathway blockade, as recommended in product specifications.
• Marker assessment: Evaluate C3, S100A10, SIRT3, and cytokine expression via qPCR, immunofluorescence, and western blot at 24–48 hours post-treatment.
• Control conditions: Include CM from naïve microglia and vehicle controls for all interventions to ensure result specificity.

Research Support Resources

For researchers aiming to reproduce or extend these findings, high-purity Azilsartan (TAK-536) is available from APExBIO (SKU B2210). This compound is a potent, selective AT1 antagonist with an IC50 of 2.6 nM, DMSO solubility, and quality control documentation, enabling reliable modeling of RAS-driven neuroinflammatory pathways. Its use is well-supported in astrocyte–microglia systems, aligning with both the reference study and best-practice protocols from recent workflow articles. Employing Azilsartan for cardiovascular research, inflammation studies, or reactive astrocyte models can enhance experimental rigor and data reproducibility.